Literature DB >> 8486957

Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.

S J Ceesay1, S J Allen, A Menon, J E Todd, K Cham, G M Carlone, S H Turner, L L Gheesling, W DeWitt, B D Plikaytis.   

Abstract

Antibodies to group A meningococcal polysaccharide were measured by hemagglutination (HA) and by ELISA in sera obtained from Gambian children before vaccination and 3 weeks, 2 years, and 5 years after vaccination with a group A + group C meningococcal capsular polysaccharide vaccine. Children were 1-4 years old at the time of vaccination. Most showed a good initial response to vaccination, including those aged 1-2 years. However, antibody titers declined progressively during follow-up, and 5 years after vaccination, antibody titers measured by both HA and ELISA had returned to prevaccination levels. This decline was not influenced significantly by a booster dose of vaccine given 2 years after initial immunization. Administration of malaria chemoprophylaxis reduced the rate at which antibody levels fell after initial immunization. Sustained protection of children against group A meningococcal disease will require the development of vaccines that are immunogenic in infants and that can induce T cell memory.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486957     DOI: 10.1093/infdis/167.5.1212

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Statement on meningococcal vaccination for travellers. Committee to Advise on Tropical Medicine and Travel.

Authors: 
Journal:  CMAJ       Date:  1995-08-01       Impact factor: 8.262

3.  Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

Authors:  J Wang; G A Jarvis; M Achtman; E Rosenqvist; T E Michaelsen; A Aase; J M Griffiss
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 4.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

5.  Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine.

Authors:  P A García-Ojeda; M E Monser; L J Rubinstein; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.

Authors:  L J Rubinstein; P A García-Ojeda; F Michon; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

8.  Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic.

Authors:  P Kriz; J Vlckova; M Bobak
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

Review 9.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

10.  Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria.

Authors:  Pablo A García-Ojeda; Sharon Hardy; Steven Kozlowski; Kathryn E Stein; Ian M Feavers
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.